🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up

Published 01/08/2020, 09:00 PM
Updated 07/09/2023, 06:31 AM

Verastem, Inc. (NASDAQ:VSTM) announced that it has signed a global licensing agreement with Japan-based Chugai Pharmaceutical. Per the terms of the agreement, Verastem will gain worldwide development and commercialization rights to Chugai’s RAF/MEK inhibitor, CH5126766. Chugai is currently developing the candidate as a treatment of KRAS mutant solid tumors.

Verastem will pay Chugai $3 million in upfront payment along with royalties. Verastem will be responsible for future development of CH5126766 and its commercialization globally. The company may look for various partnering strategies for development of the candidate.

Investors cheered the news and shares were up 36.5% on Jan 8. However, the company’s shares have declined 58% in the past year compared with the industry’s decrease of 2.9%.

Synergry has been observed in pre-clinical KRAS mutant models for combination of FAK and MEK inhibitors. Based on this observation the company has gained rights to CH5126766 for developing it in combination with its FAK inhibitor, defactinib. Currently, CH5126766 in combination with defactinib is being evaluated in a phase I/II study in patients with KRAS mutant advanced solid tumors, including low grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC) and colorectal cancer.

The company plans to present clinical data from a study on defactinib plus CH5126766 and discuss development plans and registration path for this regimen with regulatory authorities in the first half of 2020.

Verastem is also developing defactinib as monotherapy or in combination regimens for ovarian cancer, pancreatic cancer, mesothelioma, NSCLC and other solid tumors. The candidate is being evaluated in combination with Merck's (NYSE:MRK) PD-1 inhibitor Keytruda and Eli Lilly’s (NYSE:LLY) chemotherapy, Gemzar, for treating patients with advanced pancreatic cancer.

Meanwhile, Versatem continues to develop its leukemia drug, Copiktra, into additional indications including non-Hodgkin lymphoma, lung cancer, peripheral T-cell lymphoma, and others. In 2016, Verastem had in-licensed Copiktra from Infinity Pharmaceuticals (NASDAQ:INFI) . The drug received FDA approval in 2018 for treating chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two prior therapies and follicular lymphoma after at least two prior systemic therapies. The drug generated $8.7 million in sales in the first nine months of 2019.

Zacks Rank

Verastem currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.

This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.

See their latest picks free >>

Merck & Co., Inc. (MRK): Free Stock Analysis Report

Eli Lilly and Company (LLY): Free Stock Analysis Report

Verastem, Inc. (VSTM): Free Stock Analysis Report

Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.